Escoda Llorens Xavier, Anadon Cámara Eduard, Llorens Bárbara Núria, Rodríguez-Pizá Ignacio
Oncology service. AniCura Glòries Hospital Veterinari, Barcelona, Spain.
Human Evolution and Cognition Group (EvoCog), University of the Balearic Islands, Palma de Mallorca, Spain.
Vet Med Sci. 2025 Mar;11(2):e70291. doi: 10.1002/vms3.70291.
Subcutaneous mast cell tumours (ScMCTs) have been traditionally associated with a good prognosis, with low rates of recurrence and metastasis.
This study aims to describe the clinical presentation, outcome, and prognostic factors in dogs diagnosed with ScMCTs and treated with a curative-intent approach.
Clinical and histopathological data were retrospectively collected from dogs diagnosed with ScMCTs after undergoing curative-intent surgery and complete staging between 2018 and 2023 in a single institution. Adjuvant and neoadjuvant therapies were allowed. The study's endpoints were the disease-free interval (DFI) and disease-specific survival time (DSST). Variables, including location, histopathological description, clinical stage, infiltrative behaviour, atypia, Darier's sign, surgical margins, mitotic count (MC) >4 in 10 high power fields (HPF), nodal status, and chemotherapy after surgery, were evaluated as potential influences on DFI and DSST.
Thirty-two cases were included. Lymphadenectomies were performed in 18/32 (56.3%), and nodal metastases (early or overt) were documented in 12/32 (37.5%). The median follow-up was 405 days (range 79-1312). In 9/32 (28.1%), the disease progressed, and 7/32 (21.9%) died of ScMCT-related causes. The median DFI and DSST were not reached at 1312 days. The overall 1-year and 2-year survival rates were 80% and 70%, respectively. Patients presenting with Darier's sign, MC >4 in 10 HPF, and those who received chemotherapy had a higher risk of dying from the disease (hazard ratios of 14.9, 5.8 and 8.4, respectively).
Our results suggest that despite the overall good long-term prognosis of ScMCTs, they may exhibit a higher metastatic rate at presentation than previously reported. Additionally, patients with Darier's sign or a high mitotic count may be associated with a poorer prognosis.
传统观点认为皮下肥大细胞瘤(ScMCTs)预后良好,复发和转移率较低。
本研究旨在描述经根治性手术治疗的犬ScMCTs的临床表现、转归及预后因素。
回顾性收集2018年至2023年在单一机构接受根治性手术及完整分期诊断为ScMCTs的犬的临床和组织病理学数据。允许进行辅助和新辅助治疗。研究终点为无病生存期(DFI)和疾病特异性生存时间(DSST)。评估包括肿瘤位置、组织病理学描述、临床分期、浸润行为、异型性、 Darier征、手术切缘、每10个高倍视野(HPF)有丝分裂计数(MC)>4、淋巴结状态及术后化疗等变量对DFI和DSST的潜在影响。
纳入32例病例。18/32(56.3%)进行了淋巴结切除术,12/32(37.5%)记录有淋巴结转移(早期或明显转移)。中位随访时间为405天(范围79 - 1312天)。9/32(28.1%)疾病进展,7/32(21.9%)死于ScMCT相关原因。1312天时未达到中位DFI和DSST。总体1年和2年生存率分别为80%和70%。出现Darier征、每10个HPF的MC>4以及接受化疗的患者死于该疾病的风险更高(风险比分别为14.9、5.8和8.4)。
我们的结果表明,尽管ScMCTs总体长期预后良好,但与之前报道相比,其在初诊时可能具有更高的转移率。此外,出现Darier征或有丝分裂计数高的患者预后可能较差。